Titre : | The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic (2003) |
Titre traduit : | (Pharmacologie clinique de la buprenorphine. Du laboratoire au traitement) |
Auteurs : | S. L. WALSH ; T. EISSENBERG |
Type de document : | Article : Périodique |
Dans : | Drug and Alcohol Dependence (Vol.70, n°2 Suppl., May 2003) |
Article en page(s) : | S13-S27 |
Note générale : |
Drug and Alcohol Dependence, 2003, 70, (2, Suppl. 1), S13-S27 |
Langues: | Anglais |
Discipline : | TRA (Traitement et prise en charge / Treatment and care) |
Mots-clés : |
Thésaurus mots-clés OPIACES ; BUPRENORPHINE ; NALOXONE ; PHARMACOTHERAPIE ; DEPENDANCE PHYSIQUE ; TOLERANCE ; PHARMACOLOGIE |
Résumé : |
ENGLISH : This paper will review clinical pharmacology studies on buprenorphine, a mixed opioid agonist-antagonist currently approved as a treatment for opioid dependence. The focus is on studies characterizing buprenorphine's pharmacodynamic actions, including its safety, abuse liability, withdrawal suppression and withdrawal precipitation capacity, physical dependence potential, cross-tolerance and duration of action as well as a review of the pharmacological profile of buprenorphine/naloxone combinations. The findings from these clinical pharmacology studies are synthesized and presented in a framework designed to (1) inform clinicians about the advantages and disadvantages of buprenorphine as an opioid maintenance agent, and (2) provide information about dosing procedures that may optimize the use of buprenorphine in the clinic. (Review's abstract.) |
Note de contenu : | fig. |
Domaine : | Drogues illicites / Illicit drugs |
Refs biblio. : | 82 |
Affiliation : |
Behavioral Pharmacology Research Unit, Dept. Psychiatr. Behav. Sci., J. Hopkins Univ., 5510 Nathan Shock Drive, Baltimore, MD 21224 Etats-Unis. United States. |
Numéro Toxibase : | 804401 |
Centre Emetteur : | 08 CAS Strasbourg |
Accueil